Clinical Trials Logo

Clinical Trial Summary

This study is prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods. The volunteers received, in each period, the reference or the test formulation, according to the randomization list, under fasting conditions, in order to evaluate if the reference and test formulations are bioequivalent.


Clinical Trial Description

This study is prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 seuqences and 02 periods. The objective is to confirm if two formulations of topiramate 100 mg, coated tablet, are bioequivalent, after oral, single-dose administration under fasting conditions. The test product is topiramate 100 mg produced by Dr. Reddy's Laboratories Ltd. and the reference product is Topamax® marketed by Janssen-Cilag Farmacêutica Ltda. Twenty-eight healthy male volunteers were evaluated. The volunteers received, in each period, the test or the reference formulation, according to the randomization list. In each period, blood samples are collected in the following times: 00:00 (prior to the administration of medication); 00:20; 00:40; 01:00; 01:30; 02:00; 02:30; 03:00; 03:30; 04:00; 05:00; 06:00; 08:00; 12:00; 16:00; 20:00; 24:00; 48:00; 72:00; 96:00; 120:00; 144:00; 168:00; 192:00. The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01439438
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date July 22, 2011
Completion date September 11, 2011

See also
  Status Clinical Trial Phase
Recruiting NCT04770337 - Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy N/A
Terminated NCT03831802 - Embrace and Quality of Life N/A
Withdrawn NCT04282681 - XLTCS - Accelerometer Data Collection in an Epilepsy Monitoring Unit (EMU)
Completed NCT00150787 - Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy. Phase 3
Completed NCT00231556 - A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy Phase 3
Completed NCT03446664 - Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study N/A
Completed NCT00104416 - Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures Phase 3
Completed NCT00043901 - Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug Phase 4
Completed NCT00150813 - Monotherapy With Levetiracetam in Patients Suffering From Epilepsy. Phase 3